Treatment With SU11248 in Patients With Neuroendocrine Tumors

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Histologically or cytologically proven diagnosis of carcinoid tumor or pancreatic islet cell tumor.

• Evidence of unidimensionally measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST).

• ECOG performance status 0 or 1

Exclusion Criteria:

• Diagnosis of small-cell carcinoma, pheochromocytoma/paraganglioma, Merkel cell carcinoma, or any other second malignancy within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri.

• Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors. Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted.